Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 1/2 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 14Thoracic 4Gynecologic 2Breast 2Sarcoma 1Genitourinary 1CNS 1

Conditions

Breast Neoplasms 2

Interventions

Cyclophosphamide 423Trastuzumab 414Paclitaxel 375Docetaxel 314Capecitabine 266Letrozole 262Carboplatin 257Doxorubicin 213Tamoxifen 184Fulvestrant 176Epirubicin 176Radiotherapy 171Anastrozole 164pembrolizumab 152pertuzumab 147Surveys and Questionnaires 146Exercise 142exemestane 128Vinorelbine 127palbociclib 124Bevacizumab 123Magnetic Resonance Spectroscopy 120Blood Specimen Collection 120Drug Therapy 106Albumin-Bound Paclitaxel 105Gemcitabine 99130-nm albumin-bound paclitaxel 98pyrotinib 92eribulin 90Biopsy 88

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Receptor Protein-Tyrosine Kinases × Breast × Clear all
NCT00681993 2019-01-22

PBIC

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase NA Completed
35 enrolled
Breast

Breast Neoplasms

NCT00677326 2009-12-29

Histocompatibility Leukocyte Antigen (HLA)-A*0201 Restricted Peptide Vaccine Therapy in Patients With Breast Cancer

Tokyo University

Phase 1/2 Terminated
1 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡